Scarica l'app Stockscreener
26.15
8.21%
-2.34
Dopo l'orario di chiusura:
26.15
Arcus Biosciences Inc Borsa (RCUS) Ultime notizie
Arcus Biosciences at cantor global healthcare conference: casdatifan in focus By Investing.com - Investing.com Canada
Arcus Biosciences Announces New Employment Inducement Grants - marketscreener.com
Arcus Biosciences at Citi summit: casdatifan data loom large By Investing.com - Investing.com India
Following VIRO 2025 Success, Arcus Biosciences Continues Partnership in 2026 - oncodaily.com
RCUS Reiterated by Truist Securities -- Price Target Raised to $40 - GuruFocus
Truist raises Arcus Biosciences stock price target on trial data By Investing.com - Investing.com Canada
Understanding the Setup: (RCUS) and Scalable Risk - Stock Traders Daily
Arcus Biosciences Inc. (RCUS) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Arcus Biosciences Inc. (RCUS) Peer Comparison – Compare with Others - Value Research
Arcus Biosciences Inc. (RCUS) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Arcus Biosciences will take part in 3 New York conferences in September - Stock Titan
Why Arcus Biosciences (RCUS) Is Getting Attention Today - Sahm
Arcus Biosciences (RCUS) Slides 3.7% as Biotech Sector Volatility PersistsCatalyst Driven Stocks - dars.gov.et
Arcus Biosciences CAO Azoy sells $84,810 in stock By Investing.com - Investing.com Nigeria
Arcus Biosciences (NASDAQ: RCUS) CAO sells shares from option plan - Stock Titan
Arcus Biosciences CAO Azoy sells $84,810 in stock - Investing.com
Arcus Biosciences (RCUS) officer eyes sale after June plan trades - Stock Titan
Arcus Biosciences (RCUS) Stock Looks Strong On Returns But Stretched On Sales - Sahm
Investigation launched into Arcus Biosciences o... - Pluang
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm - Morningstar
Handelsbanken Fonder AB Takes $1.20 Million Position in Arcus Biosciences, Inc. $RCUS - MarketBeat
What Arcus Biosciences (RCUS)'s Steep Revenue Drop and 2026 Guidance Cut Means For Shareholders - webull.com
Arcus Biosciences Inc (RCUS) (Q2 2026) Earnings Call Highlights: - GuruFocus
Arcus Biosciences (RCUS) Advances 2.15% as Oncology Pipeline Momentum BuildsEMA Signal - vinanet.vn
Arcus Biosciences (RCUS) Reported Q2 2026 Results, Is The Stock A Bargain? - Sahm
Arcus Biosciences (RCUS) Gains Nearly 2% as Shares Trade Near Key Resistance at $30.90Call Dominated - vinanet.vn
Arcus Biosciences, Inc. Stock 12‑Month Price Target Raised to $38.82, Implies 35% Upside - TradingView
Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)’s Cancer Drug Partnership Create a New Treatment Standard? - Yahoo Finance
Arcus Biosciences, Inc. (RCUS) Stock Forecasts - finance.yahoo.com
Arcus Biosciences (RCUS) Q2 2026 Earnings Call Transcript - The Globe and Mail
(RCUS) Volatility Zones as Tactical Triggers - Stock Traders Daily
A New Arcus Employee Receives Options With a $28.72 Exercise Price - Stock Titan
Morgan Stanley Adjusts Price Target on Arcus Biosciences to $23 From $22, Maintains Equalweight Rating - Yahoo Finance
HC Wainwright Issues Optimistic Forecast for RCUS Earnings - MarketBeat
Goldman Sachs Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Raises Target Price to $42 - Moomoo
Arcus Biosciences Q2 Earnings Call Highlights - MarketBeat
Arcus Biosciences (RCUS) Stock Gets Fair Value Bump After Casdatifan Optimism - Yahoo Finance
A Quick Look at Today's Ratings for Arcus Biosciences(RCUS.US), With a Forecast Between $42 to $45 - moomoo.com
Arcus Biosciences (NYSE: RCUS) gets 24.7% ownership from Gilead - Stock Titan
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), NewAmsterdam Pharma Company (NAMS) and Revolution Medicines (RVMD) - The Globe and Mail
Arcus Biosciences Inc (RCUS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Ocular Therapeutix (OCUL) and Arcus Biosciences (RCUS) - The Globe and Mail
RCUS Maintained by Wells Fargo -- Price Target Raised to $26.00 - GuruFocus
Arcus Biosciences (NYSE:RCUS) Price Target Raised to $26.00 - MarketBeat
RCUS Maintained by Wedbush -- Price Target Raised to $43.00 - GuruFocus
Arcus Biosciences, Inc. Stock 12‑Month Price Target Raised to $38.25, Implies 38% Upside - TradingView
Wedbush Adjusts Price Target on Arcus Biosciences to $43 From $41, Maintains Outperform Rating - Yahoo Finance
Arcus Biosciences, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Arcus Biosciences Inc (RCUS) News, Articles, Events & Latest Updates - Stocktwits
Arcus Biosciences (RCUS) Stock Can Casdatifan Carry Mounting Losses - webull.com
RCUS Looks 129.7% Overvalued on GF Value™ - GuruFocus
RCUS SWOT Analysis: Financial Struggles and Competitive Pressures Revealed in 10-Q Filing - GuruFocus
Earnings call transcript: Arcus Biosciences tops Q2 2026 estimates, shares rise - Investing.com Canada
Arcus Biosciences (NYSE:RCUS) Releases Earnings Results, Beats Expectations By $0.17 EPS - MarketBeat
Arcus Biosciences, Inc. 2026 Q2ResultsEarnings Call Presentation (NYSE:RCUS) 2026-08-05 - Seeking Alpha
Arcus Q2 2026 slides: casdatifan leads oncology, immunology push - Investing.com
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
RCUS: Casdatifan advances as a potential RCC backbone therapy, supported by robust cash and key data ahead - TradingView
Arcus Biosciences, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (RCUS) Arcus Biosciences, Inc. Reports Q2 Revenue $41.0M - marketscreener.com
Arcus Biosciences Q2 revenue falls sharply on lower license income - TradingView
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):